Free Alerts   Login
Health Care › Pharmaceutical Preparations

DVAX Stock Price Correlated With Dynavax Technologies Financials

DVAX Stock Price vs. Quarterly
DVAX
Income Statement
Cash Flow
Balance Sheet

DVAX Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

DVAX Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

DVAX Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
23,396,930 sh
2,154,461 sh
10%
$327,088
$13,339
Federated Hermes.
11,364,666 sh
-1,264,059 sh
-10%
$158,878
-$27,648
State Street
9,495,785 sh
1,239,597 sh
15%
$132,751
$10,807
Vanguard Group
9,275,788 sh
128,897 sh
1%
$129,676
-$5,424
Deep Track Capital
7,093,214 sh
535,398 sh
8%
$99,163
$14,436
Chicago Capital
5,693,329 sh
-98,406 sh
-2%
$79,593
-$5,951
Dimensional Fund Advisors
4,032,139 sh
293,337 sh
8%
$56,372
$1,151
Goldman Sachs Group
3,597,139 sh
644,428 sh
22%
$50,288
$6,677
Eventide Asset Management
2,893,435 sh
1,468,435 sh
103%
$40,450
$19,403
Geode Capital Management
2,820,898 sh
120,062 sh
4%
$39,441
-$455
Morgan Stanley
2,503,122 sh
460,839 sh
23%
$34,994
$4,829
Blair William
2,409,215 sh
-60,976 sh
-2%
$33,681
-$2,804
Renaissance Technologies
1,938,078 sh
303,049 sh
19%
$27
$3
Rock Springs Capital Management Lp
1,675,474 sh
-138,284 sh
-8%
$23,423
-$11
Driehaus Capital Management
1,605,453 sh
-16,857 sh
-1%
$22,444
-$1,518
Kynam Capital Management
1,514,383 sh
1,514,383 sh
NEW
$21,171
$21,171
Northernrp
1,403,963 sh
-42,765 sh
-3%
$19,628
-$1,741
Fisher Asset Management
1,389,950 sh
-272,072 sh
-16%
$19,432
-$5,116
Woodline Partners Lp
1,289,692 sh
-492,706 sh
-28%
$18,030
-$4,999
Charles Schwab Investment Management
1,064,002 sh
-17,787 sh
-2%
$14,875
-$1,103
COMPANY PROFILE
1. Organization

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”), is a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines. Our first marketed product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted) is approved in the United States and European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. We also manufacture and sell CpG 1018®, the adjuvant used in HEPLISAV-B. We are working to develop CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, seasonal influenza, universal influenza and shingles. We reincorporated in Delaware in 2000.

Free historical financial statements for Dynavax Technologies Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 48 quarters since 2012. Compare with DVAX stock chart to see long term trends.

Data imported from Dynavax Technologies Corp SEC filings. Check original filings before making any investment decision.